Palonosetron, second generation 5-HT3 antagonist: a new perspective in CINV management

Published: June 8, 2009
Abstract Views: 181
PDF: 206
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

It is well established that the majority of cancer patients who undergo moderately or highly emetogenic cytotoxic treatment without receiving prophylactic antiemetics will experience chemotherapy-induced nausea and vomiting (CINV). Although the exact mechanisms of CINV are not fully known, it is clear from preclinical experiments and more than 15 years of clinical investigations that serotonin plays a major role in initiating nausea and vomiting associated with emetogenic chemotherapy. Emetogenic chemotherapy damages the gastrointestinal mucosa, causing the release of serotonin (5-hydroxytryptamine [5-HT]) from enterochromaffin cells in the small intestine, which, in turn, activates 5-HT3 receptors located on vagal afferents.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Piccaluga, P. (2009). Palonosetron, second generation 5-HT3 antagonist: a new perspective in CINV management. Hematology Meeting Reports (formerly Haematologica Reports), 2(7). https://doi.org/10.4081/hmr.v2i7.414